Mission Statement, Vision, & Core Values (2026) of Sandoz Group AG.

From its founding in 1886 to the landmark spin-off in October 2023, Sandoz Group AG stands at the crossroads of legacy and ambition-boasting a portfolio of roughly 1,500 products that deliver some 800 million patient treatments annually and generated net sales of USD 9.6 billion in 2023-an impressive platform for a company that pioneered the world's first oral penicillin in 1951 and the first biosimilar in 2006; today, with more than 20,000 employees from over 100 nationalities based in Basel and across global markets, Sandoz's mission to pioneer access through affordable, high-quality generics and biosimilars, its vision to become the global leader in the space, and core values of integrity, inclusion, innovation and collaboration shape a strategic roadmap aimed at expanding biosimilars, driving sustainable growth, and widening patient access worldwide.

Sandoz Group AG (0SAN.L) Intro

• Founded: 1886 (Switzerland)
• Headquarters: Basel, Switzerland
• Spin-off: October 2023 - independent from Novartis
• 2023 Net sales: USD 9.6 billion
• Global reach: ~800 million patient treatments annually
• Portfolio size: ~1,500 products across therapeutic areas (infectious disease to oncology)
• Workforce: >20,000 employees representing ~100 nationalities
• Historical innovations: world's first oral penicillin (1951); first biosimilar (2006)

• Mission - Increase access to high-quality medicines worldwide by delivering affordable generics and biosimilars at scale, enabling sustainable healthcare systems.
• Vision - Be the global leader in off-patent medicines and biosimilars, transforming patient care through affordability, reliability, and scientific excellence.
• Core values:
  • Patient-centricity: prioritize patient access, safety, and outcomes.
  • Quality & compliance: maintain stringent manufacturing and regulatory standards.
  • Innovation in off-patent science: invest in biosimilars, formulations, and cost-effective manufacturing.
  • Operational excellence: drive efficiency across supply chain and production to lower prices.
  • Diversity & inclusion: foster a multicultural workforce (>100 nationalities) and equitable opportunities.
  • Sustainability & responsibility: commit to environmental and social governance in global operations.

Sandoz Group AG (0SAN.L) Overview

• Mission focus: Affordable, high-quality generics and biosimilars to increase patient access worldwide.
• Strategic priorities: Grow biosimilars portfolio, expand in emerging markets, optimize manufacturing and supply chains, and invest in targeted R&D.
• Quality & compliance: Continued investments in regulatory compliance and manufacturing modernization to meet global standards.
• Commercial approach: Balancing price competitiveness with therapeutic coverage across key markets (US, EU, APAC, LATAM).

• Portfolio expansion: Accelerating biosimilars launches (oncology, immunology, endocrinology) to capture higher-margin, durable market segments.
• Affordability actions: Tiered pricing strategies, partnerships with health systems, and targeted access programs in lower-income countries.
• Manufacturing footprint: Investments in capacity upgrades and quality remediation programs to secure supply and regulatory compliance.
• Strategic M&A and alliances: Acquisitions and licensing deals to fill pipeline gaps and secure biosimilar development assets.

• Revenue growth from biosimilars: target double-digit CAGR over multi-year horizon.
• Gross margin improvement driven by higher-value biosimilars and manufacturing efficiencies.
• Reduction in time-to-market for key biosimilars through streamlined development and regulatory pathways.
• Access metrics: number of countries with expanded low-cost availability and patient-assistance program reach.

Sandoz Group AG (0SAN.L) Mission Statement

• Affordability & access: Prioritize cost-effective therapies to reach underserved populations.
• Biosimilar leadership: Scale R&D and regulatory capabilities to accelerate approvals and launches.
• Quality & compliance: Maintain rigorous manufacturing and quality controls across all facilities.
• Global expansion: Target growth in emerging markets while strengthening presence in established markets.

• Pipeline expansion: Continued investment to advance biosimilars (monoclonal antibodies, insulin analogues, and other high-value biologics).
• Manufacturing scale: Multiple global production sites and technology-transfer programs to reduce time-to-market.
• Regulatory expertise: Leveraging established pathways and global regulatory relationships to speed approvals.
• Financial capacity: Strong balance-sheet positioning enabling multi-year investment programs.

• Cash flow and capital allocation: Sustained operating cash flow supports multi-year biosimilar development programs and capacity investments.
• Cost efficiencies: Scale and optimized manufacturing lower unit costs, enabling competitive pricing without sacrificing margin.
• Strategic M&A and partnerships: Financial flexibility to pursue targeted acquisitions, licensing, and co-development agreements to fill pipeline gaps.

• Advocacy: Engage with payers and policymakers to expand biosimilar uptake and reimbursement pathways.
• Pricing strategies: Work with health systems to implement sustainable pricing that balances affordability and incentives for innovation.
• Access programs: Deploy targeted patient-access initiatives in lower-income regions to drive uptake and health outcomes.

Sandoz Group AG (0SAN.L) - Vision Statement

• Integrity - adherence to high ethical standards in manufacturing, regulatory compliance, and clinical practice.
• Inclusion - fostering diverse teams and equitable opportunity across functions and geographies.
• Make a Difference - patient-centered outcomes drive product portfolios and access initiatives.
• Teamwork & Collaboration - cross-functional and cross-border collaboration to accelerate launches and improve supply resilience.
• Innovation - continuous investment in formulation, biologics and manufacturing technologies to remain at the forefront of pharmaceutical advancements.
• Social Responsibility - commitments to affordability, global health partnerships and sustainable operations.

• Decision-making: Governance and compliance frameworks prioritize patient safety and regulatory integrity across ~50 manufacturing sites.
• Diversity & Inclusion: Global workforce policies support gender balance and geographic representation across ~100+ markets, enhancing creativity and problem solving.
• Innovation pipeline: Focus on biosimilars and complex generics to expand therapeutic access while controlling healthcare costs.
• Stakeholder engagement: Transparent reporting and partnerships with health systems, NGOs and governments to improve affordability and supply continuity.

• Portfolio prioritization: Resources directed toward high-impact biosimilars and complex generics that increase patient access while delivering sustainable returns.
• Operational excellence: Investments in manufacturing scale and quality systems to uphold integrity and reduce supply interruptions.
• People & culture: Inclusion and teamwork initiatives to retain talent and foster cross-disciplinary innovation.
• External partnerships: Collaborative deals with payers, NGOs and health systems to translate affordability commitments into measurable access outcomes.